JP, another thing I'd like to point out is, if SeD Biomedical, who's stated purpose is to assist in the funding and restructuring of biotechnology companies, is committed to an Amarantus turnaround, that is a big impediment to Magna et al collecting through the BK, carve up scenario you describe. In normal circumstances, shareholders always try to oppose being cut out. It's simply almost always to difficult to band together enough parties with the money and will to effectively challenge the claims of creditors. SeD has the resources, and might have the will to draw out such a circumstance, costing Magna et al significant costs.
You continue to mention that AMBS has to come up with 16-17M dollars. They certainly do not, the LOI speaks to this fact, that on principle, parties agreed to take over certain AMBS assets in exchange for clearing the books. No doubt, AMBS has accumulated several millions in payables, and needs funding after that, but with a clear cap structure and all the scientific progress on MANF, elto, and administration, this is not nearly as difficult to imagine as it was when AMBS was forced, or dummied into the toxics 2 years ago. Future is bright man, much brighter that a year ago.
I described a realistic and moderately conservative scenario on the other board where we walk out of here with effectively $0.25-0.40 shares and a solid foundation for growth. Many unknowns remain. But this is gonna happen, just like CHF turned SeD around, he is going to turn Amarantus around and share in our success. He's not Warren Buffett. But then again, we're not Bank of America. He's a well-resourced, well-intentioned man who has declared his will.
